Alpha9 Theranostics
AT
AL

Alpha9 Theranostics

ClaimedAgent22Agent Readiness: 22/100. Bottom 25%. Measured by StartupHub.ai. Median 41.

Developing novel radiopharmaceuticals for targeted cancer treatment using advanced molecular imaging and therapy.

Website
2017InactiveVancouver, Canada

About

Alpha9 Theranostics is a biotechnology company focused on the development of next-generation radiopharmaceuticals for the diagnosis and treatment of cancer. They leverage their expertise in molecular imaging and targeted delivery to create innovative theranostic agents that can precisely identify and eliminate cancer cells.

Key facts

At-a-glance profile data

Website
alpha9.com
Headquarters
Vancouver, Canada
Founded
2017
Total funding
$10M (Seed)
Business model
B2B

Funding rounds

Funding rounds raised by Alpha9 Theranostics
DateRoundAmountLead investors
1 Jun 2021Seed$10M-
Add first review

Frequently asked

How much funding has Alpha9 Theranostics raised?

Alpha9 Theranostics has raised a total of $10M in funding. The most recent round on record is Seed.

What is Alpha9 Theranostics's current status?

Alpha9 Theranostics's current operating status is: Inactive.